BMS Access Support® may help support patient access by conducting benefits reviews and offering prior authorization and appeals process assistance for enrolled patients. Additionally, the information below provides product-specific billing and diagnosis codes, reimbursement and coding guides, distribution information, and additional coverage support offerings. To view available coding and coverage information, please select your patient’s prescribed medication.
Additional eligibility criteria and terms may apply. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.
Read more about our coverage support offeringsBenefits Reviews
*BMS Access Support Data - Benefits review. Accessed August 2022.
Prior Authorization (PA) and Appeals Assistance
Annual Reverification
The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.
Reimbursement and Coding Guide
for SPRYCEL
Filter results by:
National Drug Codes (NDC)1
Issued by the FDA
Note: Payers require the submission of the 11-digit NDC on healthcare claim forms. Please use the 11-digit codes shown here.
00003-0527-11 Copy | 20 mg tablet, 60 tablets per bottle |
00003-0528-11 Copy | 50 mg tablet, 60 tablets per bottle |
00003-0524-11 Copy | 70 mg tablet, 60 tablets per bottle |
00003-0855-22 Copy | 80 mg tablet, 30 tablets per bottle |
00003-0852-22 Copy | 100 mg tablet, 30 tablets per bottle |
00003-0857-22 Copy | 140 mg tablet, 30 tablets per bottle |
International Classification of Diseases, Tenth Revision, Clinical Modification Diagnosis Codes (ICD-10-CM)2
Adult and Pediatric Chronic Myeloid Leukemia | |
C92 | Myeloid leukemia |
C92.1 | Chronic myeloid leukemia (CML), BCR/ABL-positive† |
C92.10 | CML, BCR/ABL-positive, not having achieved remission |
C92.11 | CML, BCR/ABL-positive, in remission |
C92.12 | CML, BCR/ABL-positive, in relapse |
Adult Acute Lymphoblastic Leukemia | |
C91 | Lymphoid leukemia |
C91.0 | Acute lymphoblastic leukemia (ALL)† |
C91.00 | ALL, not having achieved remission |
C91.01 | ALL, in remission |
C91.02 | ALL, in relapse |
Pediatric Acute Lymphoblastic Leukemia | |
C91 | Lymphoid leukemia |
C91.0 | Acute lymphoblastic leukemia (ALL)† |
C91.00 | ALL, not having achieved remission |
C91.01 | ALL, in remission |
*Healthcare providers should code healthcare claims based upon the service that is rendered, the patient’s medical record, the coding requirements of each health insurer, and best coding practices. Coding guidance provided under this heading does not provide a guarantee of reimbursement and should be considered together with all applicable coding guidance and standards. All of the coding information presented by this website is applicable to outpatient procedures only.
†This is a category code and is invalid for stand-alone use.
References: